about
Dynamic contrast-enhanced MRI: Study of inter-software accuracy and reproducibility using simulated and clinical data.Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis.Can dynamic contrast-enhanced magnetic resonance imaging combined with texture analysis differentiate malignant glioneuronal tumors from other glioblastoma?Pentoxifylline aggravates fatty liver in obese and diabetic ob/ob mice by increasing intestinal glucose absorption and activating hepatic lipogenesis.Blocking Wnt signaling by SFRP-like molecules inhibits in vivo cell proliferation and tumor growth in cells carrying active β-catenin.ViP MRI: virtual phantom magnetic resonance imaging.Towards a patient-specific hepatic arterial modeling for microspheres distribution optimization in SIRT protocol.Coupling texture analysis and physiological modeling for liver dynamic MRI interpretation.Computational modeling of MR flow imaging by the lattice Boltzmann method and Bloch equation.MRI texture analysis on texture test objects, normal brain and intracranial tumors.Preliminary MRI quality assessment and device acceptance guidelines for a multicenter bioclinical study: the GO Glioblastoma Project.In silico modeling of magnetic resonance flow imaging in complex vascular networks.Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry.A physiologically based pharmacokinetic model of vascular-extravascular exchanges during liver carcinogenesis: application to MRI contrast agents.SIMULATION OF HEPATOCELLULAR CARCINOMA IN MRI BY COMBINED MACROVASCULAR AND PHARMACOKINETIC MODELSMagnetic resonance imaging contrast-enhanced relaxometry of breast tumors: an MRI multicenter investigation concerning 100 patientsMRI quantification of splenic iron concentration in mouseImproved Transversal Relaxivity for Highly Crystalline Nanoparticles of Pure γ-Fe2O3 Phase
P50
Q31033043-041AA3A7-D0CD-4C8F-8E8D-9331FAF8624FQ35538224-A1E26D95-027F-4CEF-ADBE-7F93851255F6Q35615144-812B37BE-76D7-43C4-8D27-D4FC71952C33Q36024871-9BADEDF6-5CA4-47BD-9ACF-F02755832826Q36410444-992602A5-1DF0-4CB1-8146-E0F5657B8F3CQ37408136-B790426B-FF52-4A75-B0E8-5458DDF6113AQ38616444-0F7FB552-861D-4316-9963-BCFD2A9D7E4CQ42765775-4E43EC26-9626-418D-B555-CC5372AA09E8Q44992296-D3339EA3-C88C-4438-AB91-47753B2ECDDEQ48111948-E4051027-B295-44D3-8320-B394A35BD3DDQ48922915-F7C6CA50-2524-4D37-8A2F-843FE1005CC0Q51067440-593B654F-FBD4-424F-BA02-8FA6F25120CEQ51760390-A4FB7F42-A8DB-4DD9-95AE-B4231A168821Q53328979-9D9BBD4F-7AF2-465F-9666-B91F0743B9C2Q62038009-1AED62D5-2984-400A-8652-3AC11905F293Q80032910-48355C9B-6981-4850-8E1A-93243CBE2E63Q84977830-CD65A226-6546-4308-A9FE-8ABD47A355D0Q86636121-95D7A033-5F2E-49B5-9842-7136581F5472
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-8082-4477
@en
name
Pierre-Antoine Eliat
@ast
Pierre-Antoine Eliat
@en
Pierre-Antoine Eliat
@es
Pierre-Antoine Eliat
@nl
type
label
Pierre-Antoine Eliat
@ast
Pierre-Antoine Eliat
@en
Pierre-Antoine Eliat
@es
Pierre-Antoine Eliat
@nl
prefLabel
Pierre-Antoine Eliat
@ast
Pierre-Antoine Eliat
@en
Pierre-Antoine Eliat
@es
Pierre-Antoine Eliat
@nl
P106
P31
P496
0000-0002-8082-4477